Dyspepsia - The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study)

Simple item page
dc.contributor.authorSud, Ren_US
dc.contributor.authorPebbili, KKen_US
dc.contributor.authorDesai, SAen_US
dc.contributor.authorBhagat, Seemaen_US
dc.contributor.authorRathod, Rahulen_US
dc.contributor.authorMane, Ameyen_US
dc.contributor.authorKotak, Bhaveshen_US
dc.date.accessioned2023-06-17T08:22:57Z
dc.date.available2023-06-17T08:22:57Z
dc.date.issued2023-04
dc.description.abstractBackground: Dyspepsia includes a spectrum of symptoms ranging from epigastric pain and early satiety to postprandial fullness. The worldwide prevalence of dyspepsia is 20–30%. It is slightly higher in the Western population and occurs more frequently among women. While the precise prevalence of dyspepsia in India is not available, different studies estimate that it affects 7.6–49% of the Indian population. Through our current study, we wanted to understand the demographics, clinical profile, patient presentation, and management in India. We also wanted to document the pattern of use of proton pump inhibitors (PPI) and patient satisfaction with PPIs in Indian patients with dyspepsia. Materials and methods: This pan-India, multi-centric, cross-sectional, questionnaire-based, noninterventional, observational study was conducted between February and October 2021 in patients >18 years of age with a clinical diagnosis of any form of dyspepsia. Descriptive statistics were used for categorical variables, and between-group comparisons were made using Fischer’s exact test, with p < 0.05 denoting statistical significance. Results: A total of 3,739 patients from across 29 states of India participated in the study. Most of the patients were male (70.8%) and were from urban areas (56.8%). The highest percentage of patients were aged 31–40 (33.8%), and most patients (60.2%) had dyspepsia for a duration of 6–12 months. Patients with functional dyspepsia (FD) (78.5%) were significantly higher compared to organic dyspepsia (OD) (21.5%) (p < 0.001). The most frequent presenting symptoms were epigastric pain, nausea, vomiting, and heartburn. A quarter (25.6%) of the dyspepsia patients were associated with various comorbid conditions, of which diabetes mellitus, hypertension, and irritable bowel syndrome are the most common ones. A total of 619 patients in the study were on concomitant medications, of which the most common were antidiabetic drugs (271/619, 43.8%). Rabeprazole was the most frequently used PPI (2467/3739, 66.0%) among the study participants. The patient satisfaction analysis showed that, overall, patients were satisfied with PPIs, as most patients (~80%) agreed to almost all questions. The analysis for individual PPIs showed the highest “agree” responses in the rabeprazole group for almost all questions (12 of 13). Around 86.4% of patients on rabeprazole agreed with “immediate relief from acidity,” 84.9% for “gives me complete relief,” and 85.9% for “relief from nighttime acidity symptoms.” Conclusion: Our study involving over 3,700 Indian patients with Dyspepsia adds to the growing knowledge of dyspepsia in India. Dyspepsia is more prevalent in males and in the 31–50 age group. FD is the most common form. Overall, patients were satisfied with PPIs in dyspepsia management in India. Patients on rabeprazole showed higher levels of medication adherence, satisfaction with symptom relief, convenience of therapy, and safety compared to patients on other PPIs. Against the backdrop of a paucity of reliable data about dyspepsia in India, our study results provide valuable insights into Dyspepsia and its management in an Indian settingen_US
dc.identifier.affiliationsConsultant, Specialist Clinic, Delhien_US
dc.identifier.affiliationsCluster Head Recura Divisionen_US
dc.identifier.affiliationsMedical Advisor, Department of Medical Affairs, Dr Reddys Laboratories, Telangana, Hyderabaden_US
dc.identifier.affiliationsClinical Research Specialisten_US
dc.identifier.affiliationsCluster Head Ideation and Clinical Researchen_US
dc.identifier.affiliationsCluster Head Acute Divisionen_US
dc.identifier.affiliationsHead, Department of Medical Affairs, Dr Reddys Laboratories, Telangana, Hyderabad, Indiaen_US
dc.identifier.citationSud R, Pebbili KK, Desai SA, Bhagat Seema, Rathod Rahul, Mane Amey, Kotak Bhavesh. Dyspepsia - The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study). Journal of the Association of Physicians of India. 2023 Apr; 71(4): 36-46en_US
dc.identifier.issn0004 – 5772
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/216384
dc.languageenen_US
dc.publisherAssociation of Physicians of Indiaen_US
dc.relation.issuenumber4en_US
dc.relation.volume71en_US
dc.source.urihttps://doi.org/10.5005/japi-11001-0231en_US
dc.titleDyspepsia - The Indian perspective: A cross sectional study on demographics and treatment patterns of Dyspepsia from across India (Power 1.0 study)en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JAPI2023v71n4p36.pdf
Size:
354.92 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of the Association of Physicians of India